Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RALATOR: Atorvastatin and Raltegravir Strategy in Older HIV Patients
NCT02577042Phase 4Completed
- Start
- Oct 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Raltegravir + Atorvastatin with PI-based regimen + Atorvastatin (2 arms). Primary endpoints: Interleukin-6 at 72 weeks and D-dimer at 72 weeks. Started Oct 2015; status: completed.
02
Drugs
raltegraviratorvastatin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02577042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577042.